Investors with Significant Losses in MoonLake Immunotherapeutics Have a Chance to Lead Class Action Lawsuit

Investors Encouraged to Lead Class Action Against MoonLake Immunotherapeutics

In the wake of a significant securities fraud scandal, Rosen Law Firm has opened up an opportunity for investors who lost substantial amounts in MoonLake Immunotherapeutics (NASDAQ: MLTX). Specifically, those who purchased shares between March 10, 2024, and September 29, 2025, and suffered losses over $100,000 may qualify to lead a class action lawsuit against the biotech firm. The deadline for taking action is December 15, 2025.

What This Means For Investors

Those who bought MoonLake's common stock during the outlined period are urged to act quickly if they wish to seek compensation. The law firm has stated that they can assist investors in joining the class action lawsuit without the need for upfront costs, as they operate under a contingency fee model. This ensures that investors do not have to pay out-of-pocket expenses.

To participate, investors are directed to visit the Rosen Law Firm’s dedicated page or contact their office for more information. Active participation in the lawsuit means representing fellow investors in what could be a landmark case in the realm of securities fraud.

Why Choose Rosen Law Firm?

The Rosen Law Firm, a distinguished global advocate for investor rights, highlights the importance of selecting qualified counsel with a proven track record. They warn investors against firms that simply act as referral services instead of genuinely litigating cases. Having successfully secured one of the largest settlements from a Chinese corporation and consistently ranking at the top-level of securities class action settlements, the Rosen Law Firm stands out as a leading choice for representation in this matter.

Historically, the law firm has demonstrated its capability, having recovered hundreds of millions of dollars for investors in prior cases. For instance, in 2019 alone, they managed to secure over $438 million for their clients, highlighting their strong standing in investor advocacy.

The Allegations Against MoonLake

The allegations brought forward in the complaint revolve around misleading statements made by MoonLake concerning its products during the class period. It has been asserted that the firm failed to disclose critical information regarding the efficacy and supposed superiority of its Nanobody product, SLK, over conventional monoclonal antibodies. Specifically, claims have been made that:

1. SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F).
2. SLK does not provide any clinical benefits that surpass those of monoclonal antibodies due to its distinct structure.
3. The anticipated superior tissue penetration of SLK does not guarantee enhanced clinical efficacy.
4. There exists a lack of reasonable basis for positive endorsements regarding SLK's perceived advantages over its competitors.

When the actual facts emerged, market responses saw a significant toll on the share prices, leading investors to incur substantial losses. Many now find themselves navigating the aftermath of these revelations while contemplating their next steps. By joining the class action, they can ensure that their voices are heard in the fight for justice.

How to Join the Class Action

Interested investors can easily secure their participation in the MoonLake class action by visiting the Rosen Law Firm's submission page or by reaching out directly to Phillip Kim, Esq., through various means: via toll-free number (866) 767-3653, or by email at [email protected].

It is crucial to note that until a class is certified, representation is not guaranteed unless individuals take the initiative and select their counsel.

Conclusion

For those impacted by the allegations against MoonLake Immunotherapeutics, the approaching deadline for leading the class action presents a pivotal moment. By collaborating with experienced legal counsel and participating in the collective effort, investors can potentially reclaim their losses and bring those responsible for misinformation to account.

Stay updated with the Rosen Law Firm through LinkedIn, Twitter, and Facebook for ongoing developments and insights into the case as it unfolds.